Xuan Zhang

发表

Discovery of piperlongumine as a potential novel lead for the development of senolytic agents

Daohong Zhou, Yingying Wang, Jianhui Chang, 2016, Aging.

PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors

Daohong Zhou, Guangrong Zheng, Sajid Khan, 2020, Exploration of targeted anti-tumor therapy.

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

J. Elisseeff, J. Campisi, M. Almeida, 2020, Nature Communications.

Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity.

Daohong Zhou, Yaxia Yuan, Guangrong Zheng, 2020, European journal of medicinal chemistry.

Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL.

Daohong Zhou, Guangrong Zheng, Dinesh Thummuri, 2019, Chemical communications.

Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity

J. Campisi, Daohong Zhou, Guangrong Zheng, 2020, Aging cell.

Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation.

Daohong Zhou, Yingying Wang, H. Hendrickson, 2018, Bioorganic & medicinal chemistry.

Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216

A. Loguinov, C. Vulpe, R. Hromas, 2021, Molecular Cancer Therapeutics.

Synthesis and Liver Microsomal Metabolic Stability Studies of a Fluorine‐Substituted δ‐Tocotrienol Derivative

Daohong Zhou, H. Hendrickson, Yaxia Yuan, 2020, ChemMedChem.

Synthesis of O- and N-alkylated products of 1,2,3,4-tetrahydrobenzo[c][2,7]naphthyrin-5(6H)-one.

L. Dwoskin, Guangrong Zheng, S. Bommagani, 2015, Tetrahedron letters.

of activity selectively eliminates senescent cells in part via restoration of p53 activity.

J. Campisi, Daohong Zhou, Guangrong Zheng, 2020 .

Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice

F. Kaye, R. Hromas, Nan Hua, 2022, bioRxiv.

Recent advances in small molecular modulators targeting histone deacetylase 6

Xuan Zhang, Yufeng Xiao, 2020 .

Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs.

Lisa Y. Zhao, Daiqing Liao, Guangrong Zheng, 2020, Chemical communications.

Synthesis of (2R,8' S,3' E)-δ-tocodienol, a tocoflexol family member designed to have a superior pharmacokinetic profile compared to δ-tocotrienol.

P. Crooks, M. Boerma, Daohong Zhou, 2016, Tetrahedron.

New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.

Hui Zhang, Chunxiao Zhang, Fei Lu, 2018, Bioorganic & medicinal chemistry.

Novel Linear Lipopeptide Paenipeptins with Potential for Eradicating Biofilms and Sensitizing Gram-Negative Bacteria to Rifampicin and Clarithromycin.

M. Smeltzer, Guangrong Zheng, En Huang, 2017, Journal of medicinal chemistry.

Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition.

Daohong Zhou, Nan Hua, Yaxia Yuan, 2021, Journal of medicinal chemistry.

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics

Daohong Zhou, Yaxia Yuan, Guangrong Zheng, 2020, Oncogene.

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

R. Hromas, Daohong Zhou, Yaxia Yuan, 2020, Journal of Hematology & Oncology.

Assays and technologies for developing proteolysis targeting chimera degraders

Daohong Zhou, Yaxia Yuan, Guangrong Zheng, 2020, Future medicinal chemistry.

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

A. Ferrando, M. Konopleva, P. Houghton, 2019, Nature Medicine.

Oxidation resistance 1 is a novel senolytic target

A. Tackett, J. Campisi, Daohong Zhou, 2018, Aging cell.

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

R. Koch, D. Weinstock, Daohong Zhou, 2020, Journal of Hematology & Oncology.

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

J. Elisseeff, J. Campisi, M. Almeida, 2020, Nature Communications.

Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines.

Daohong Zhou, J. Pei, Yaxia Yuan, 2020, European journal of medicinal chemistry.

Targeting anti-apoptotic BCL-2 family proteins for cancer treatment.

Daohong Zhou, Guangrong Zheng, Xingui Liu, 2020, Future medicinal chemistry.

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

A. Ferrando, M. Konopleva, P. Houghton, 2019, Nature Medicine.

Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells

S. Zheng, Daohong Zhou, yang-xin fu, 2021, Nature Communications.

Piperlongumine (PL) conjugates induce targeted protein degradation

J. Licht, Nan Hua, J. Pei, 2023, bioRxiv.

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

M. Konopleva, R. Hromas, S. Weintraub, 2021, Nature Communications.

Deuteration of the farnesyl terminal methyl groups of δ-tocotrienol and its effects on the metabolic stability and ability of inducing G-CSF production.

P. Crooks, Daohong Zhou, H. Hendrickson, 2020, Bioorganic & medicinal chemistry.

HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation.

Daiqing Liao, Guangrong Zheng, Weizhou Zhang, 2023, Cell chemical biology.

Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216

A. Loguinov, C. Vulpe, R. Hromas, 2021, Molecular Cancer Therapeutics.

A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients

L. Jl, Si-Yi Chen, M. Liang, 2009, Gene Therapy.

Piperlongumine conjugates induce targeted protein degradation.

J. Licht, Nan Hua, J. Pei, 2023, Cell Chemical Biology.

Discovery of piperlongumine as a potential novel lead for the development of senolytic agents

Daohong Zhou, Yingying Wang, Jianhui Chang, 2016, Aging.